Why Case Mix Decides This, Not Specification

The platform that fits is the one whose wavelength and optics configuration matches the treatments the clinic will deliver. A specification advantage that the caseload does not use is cost rather than capability.

Three inputs decide the comparison. The ink colors and pigment conditions the clinic expects to treat, taken from its existing patient population rather than from a market estimate. The optics configuration included with each candidate unit, since that determines both the treatment range and the consumable position. And the service and consumable supply available for each model in that market, because a platform that cannot be calibrated or replenished stops earning on a date nobody has disclosed. Where those three are written down first, the comparison becomes arithmetic; without them, it becomes a brand preference.

Wavelength Coverage and What It Changes

Wavelength coverage sets the treatable case mix, which is why it outranks cosmetic condition in any purchase decision. Two units of different platforms offering different coverage are not substitutes for one another.

The practical method is to write the clinic’s expected treatment profile first, then test each candidate against it. Where a platform covers the profile with room to spare, that optionality has value only if the clinic expects to use it; where the platform covers exactly the profile, the purchase is efficient. Where neither covers it, the answer is that neither platform is the right answer, which the final section addresses.

Pigment and Tattoo Color Fit

Pigment fit is about matching emitted wavelength to the ink or pigment being addressed, and it is a clinical decision taken by the treating practitioner. From a procurement standpoint, what matters is whether the clinic’s expected caseload falls within the platform’s capabilities and inside its cleared intended use.

• The ink colors most commonly seen locally, and which wavelengths are needed for each.
• Whether the clinic will treat professional, amateur, or cosmetic pigment work, which differ in demand.
• Whether adjacent pigment indications will also be offered, which broadens the coverage requirement.
• Whether the platform’s intended use covers each treatment the clinic intends to market.
• Where the clinic will refer cases out, and what proportion of inquiries that represents.

Two commercial consequences follow. A platform that covers the common local inks attracts more of the demand that already exists, which shortens the ramp period. And a platform whose intended use is narrower than the treatments a clinic wants to advertise creates a marketing problem rather than a clinical one, which is why the labeling position should be confirmed before the price is agreed.

Consumables, Optics and Running Cost

Running cost on both platforms is dominated by optics and delivery components, which have finite life and are priced individually. That makes consumable cost per treatment the comparison that matters, and the console price the one that matters least.

• Cost per delivery component divided by the treatments it supports.
• Components consumed per session, which varies with treatment area and protocol.
• Any single-use accessories used per session alongside the main consumables.
• Supply lead times for replacement components, since a stockout cancels booked sessions.
• Provenance of replacements, because unverified equivalents change risk as well as cost.

The comparison should therefore be run on consumable cost per treatment at the clinic’s expected volume, not on the purchase figure. Because the console cost is fixed while component cost scales with volume, a platform with a higher capital figure and a lower component cost per treatment can be the cheaper option at adequate utilization, and the reverse is true at low volume.

Support, Parts and Service Availability

Support is what makes a platform usable over time, and it is the area where the least reliable published comparisons exist. Service capability, spare parts, and consumable supply all need to be established for the specific model and market rather than inferred from the brand.

• Who performs service and calibration, and whether capability exists independently of the original vendor.
• Parts availability and lead times, and whether supply exists through more than one channel.
• Consumable continuity for the model, including any announced end-of-life components.
• Documented maintenance intervals, benchmarked against recognized practice.
• Alert or field-safety history for the model, checked before commitment.

Maintenance expectations should be benchmarked rather than agreed informally, and bodies such as AAMI publish equipment-maintenance guidance that clinical engineering functions use to define intervals and documentation. Electrical safety expectations for medical electrical equipment sit in the IEC 60601 series, which is why an up-to-date electrical safety test record belongs in the file for any pre-owned platform, and independent alert reporting such as that published by ECRI is the customary cross-check on a model’s safety history.

Pre-Owned Availability and Price Bands

Both platforms appear on the secondary market, at prices driven by optics position, software status, and the assurance attached to the sale. Age and console hours rank below all three.

One practical difference between the routes concerns the optics set supplied. A pre-owned unit may arrive with fewer delivery components than a new package, which shifts cost into the buyer’s first months rather than out of the deal, and that timing effect matters most to clinics without working capital headroom.

A buyer comparing two pre-owned units should compare those five lines rather than two prices. Where a unit is cheap with undocumented optics and no cover, the discount is payment for risk the buyer has accepted, and it should be measured against a higher-priced unit with a verifiable delivery history.

Verification Steps for Either Platform

Verification follows the same sequence on both platforms, and the order matters because everything later is priced against a settled identity.

• Serial numbers matching across the unit, its documentation, and any service record.
• Ownership evidence, and confirmation that no finance or lease interest remains.
• Optics and handpiece history, with remaining life stated per component.
• Software release, license position, and whether the license transfers.
• Clearance and labeling documentation, and the intended use it describes.
• Service and calibration records, dated and attributed to a named provider.

Where the clearance picture is unclear, the references are jurisdiction-specific: the FDA medical device portal for US operations, and EUR-Lex for the EU position including MDR 2017/745. Claims about treatment outcomes should be assessed against the platform’s documented intended use and published literature rather than promotional material, with material from professional societies such as the American College of Radiology as a reasonable reference for how such evidence is judged.

Side-by-Side Decision Table

The table below is the comparison that should drive the decision, and it is deliberately structured around the buyer’s own clinic rather than around the platforms’ features.

Before committing to either platform, verify:

• Configuration and optics supplied, itemized against the invoice.
• Consumable cost per treatment, calculated rather than quoted.
• Supply position for optics and handpieces, with lead times.
• Service and calibration access across the planned holding period.
• Warranty or support terms in writing, with exclusions and response commitments.
• Clearance and labeling position for the intended treatments.
• Software licensing and transferability, if the unit may be resold.
• Finance structure and term, where the purchase is financed.

When Neither Platform Is the Right Answer

There are situations where the correct decision is neither option, and recognizing them prevents a purchase made for the wrong reason.

• Where the clinic’s expected case mix sits outside the coverage of both platforms.
• Where demand for the treatment is unproven and would have to be created through marketing.
• Where room or practitioner capacity cannot sustain the sessions the payback model assumes.
• Where consumable or service supply for both models is uncertain in that market.
• Where the clinic’s need is broader than pigment work, making a different category the better fit.

In those cases the productive next step is to outsource or refer the treatment out until volume is demonstrated, which produces real data at negligible cost compared with owning a platform that does not reach break-even. Where a purchase does proceed, the platform choice should be settled on the decision table above, and the requirement can be framed through the device and brand comparisons material and the modality and category selection resources before a quotation request is raised.

Questions Clinic Buyers Ask